TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 122 filers reported holding TCR2 THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $16,148 | +37.9% | 10,765 | -8.2% | 0.00% | – |
| Q4 2022 | $11,707 | -83.7% | 11,721 | -70.6% | 0.00% | – |
| Q3 2022 | $72,000 | -70.2% | 39,914 | -52.2% | 0.00% | – |
| Q2 2022 | $242,000 | -48.1% | 83,466 | -50.6% | 0.00% | – |
| Q1 2022 | $466,000 | -70.8% | 168,799 | -50.8% | 0.00% | – |
| Q4 2021 | $1,597,000 | +134.9% | 342,764 | +329.2% | 0.00% | – |
| Q3 2021 | $680,000 | -87.8% | 79,867 | -76.4% | 0.00% | -100.0% |
| Q2 2021 | $5,560,000 | -37.0% | 338,737 | -15.2% | 0.00% | -50.0% |
| Q1 2021 | $8,822,000 | +15.0% | 399,518 | +61.1% | 0.00% | 0.0% |
| Q4 2020 | $7,671,000 | +697.4% | 248,018 | +423.8% | 0.00% | – |
| Q3 2020 | $962,000 | +275.8% | 47,352 | +184.1% | 0.00% | – |
| Q2 2020 | $256,000 | -74.0% | 16,668 | -70.5% | 0.00% | – |
| Q1 2019 | $984,000 | – | 56,443 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
| Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
| Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
| Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
| PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
| Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
| MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
| Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |